Kangpu Pharmaceutical

Kangpu Pharmaceutical Co., Ltd. is a distinctive modern Chinese and Western medicine pharmaceutical enterprise integrating technology research and development, production, and sales. Its predecessor, "Hunan Kangpu Pharmaceutical Co., Ltd.," was founded in 1991 as the first Sino-foreign joint venture in Hunan Province. After more than 30 years of development, it has become a modern pharmaceutical enterprise with a national reputation. The company has been rated as a major taxpayer with over ten million yuan in profits and taxes for many consecutive years, one of the top ten pharmaceutical enterprises in Hunan Province, and is a high-tech enterprise in Hunan Province, a key backup enterprise for listing, and a "Little Giant" program enterprise. The company has modern Chinese and Western medicine pharmaceutical production bases with a total area of 273 mu, located in the Taizimiao Industrial Park in Hanshou and the Yisuhe Economic Development Zone in Xiangtan. It has production lines for multiple dosage forms including tablets, capsules, granules, small-volume water injections, freeze-dried powder injections, chemical drug synthesis, and traditional Chinese medicine extraction. As a nationally GMP-certified enterprise, it implements full-process GMP quality management to ensure product quality and safety, providing consumers with reliable-efficacy, safe-to-use products and attentive service. Kangpu has independently developed more than 100 products and owns two major product series: "Kangpu" brand chemical drugs and "Xilaile" brand Chinese patent medicines. Products cover categories such as treatments for digestive system diseases, cardiovascular and cerebrovascular diseases, liver and kidney diseases, anti-microbial infections, tonics and nutritional supplements, and active pharmaceutical ingredients. Numerous carefully manufactured products provide reliable choices for cooperation with customers and for consumers seeking treatment. Kangpu omeprazole enteric-coated capsules are a * drug for treating peptic ulcers, and their "micro-pellet technology" obtained a national invention patent; Xilaile Bushen Yishou Tablets were selected for the 2010 National Torch Program project, and their preparation process is protected by a national invention patent; Xilaile Ganfule Capsules have been included in the national medical insurance catalogue and received project support from the National Development and Reform Commission for the modernization of the traditional Chinese medicine industry. The "Kangpu," "Xilaile," and "Xinkuaikang" brands have been recognized as famous trademarks of Hunan Province, and flagship products such as omeprazole enteric-coated capsules, Bushen Yishou Tablets, and Agui Yangxue Granules have been awarded the title of Hunan Famous Brand Products. Technological innovation is the eternal source of power for the sustainable development of pharmaceutical enterprises. The company has established the province's * enterprise-run pharmaceutical research institute, has long-term cooperative relationships with well-known domestic and international research institutions and universities, and has a * enterprise technology center, postdoctoral workstation, pharmaceutical information and intellectual property center, and drug screening engineering technology research center supported by national, provincial, and municipal governments, becoming a guarantee for the company's sustainable development and one of the platforms for industry technological progress, and has successfully applied to the State Intellectual Property Office for 55 patents. The company has established Hunan Kangpu Pharmaceutical Marketing Co., Ltd., focusing on bringing Kangpu products to the national and world markets. Apart from Hong Kong, Macao, and Taiwan regions, its marketing network has covered all provinces and cities nationwide. In 2010, the company established an International Business Department and set up a Kangpu office in Vietnam, gradually opening up the Vietnamese sales market. The national market is divided into 19 inter-provincial sales regions, with more than 50 prefecture-level business representative offices and a sales team of 300 people. The company adopts multiple sales models such as channel distribution and deep terminal recruitment, has established stable cooperative relationships with more than 300 * outstanding distributors across the country, signed secondary distribution agreements with nearly 600 regional distributors nationwide, and has more than 30,000 terminal customers (chain pharmacies, independent pharmacies, urban community health service centers, rural health centers, and clinics) with which it has established business relationships. The company promptly adjusts channel strategies to adapt to the market competition environment, continuously innovates promotional methods, ensures effective coverage of products, and its main products have formed a stable market foundation with a loyal consumer group. The company adheres to the values of "integrity in business, innovation and pragmatism, eagle-and-goose teamwork, and harmonious win-win," striving to create market value while building itself into a first-class pharmaceutical brand enterprise in the province with national influence, realizing its personal value and cultural pursuit of serving humanity.